Search - tctmd.com

Displaying 141 - 160 of 344

Sort: Relevancy | Date

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

New A-fib Performance and Quality Measures Emphasize Shared Decision-Making, Inpatient and Outpatient Care

Michael O'Riordan

June 29, 2016

News Daily News

FDA Warns of Class I Recall for HeartWare VAD Batteries

Michael O'Riordan

June 29, 2016

News Daily News

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Michael O'Riordan

June 28, 2016

News Daily News

Black Individuals Have Less A-fib, but When They Do, the Consequences Are More Dire

Michael O'Riordan

June 24, 2016

News Daily News

TAVR 后持续低流量主动脉瓣狭窄与较高的 1 年死亡率相关

Michael O'Riordan

June 23, 2016

News Daily News

Persistent Low-Flow Aortic Stenosis After TAVR Linked With Higher 1-Year Mortality

Michael O'Riordan

June 23, 2016

News Daily News

La Estenosis Aórtica Persistente de Bajo Flujo Post-TAVR se asocia a una Mortalidad Más Alta al cabo de 1 Año

Michael O'Riordan

June 23, 2016

News Conference News TVT 2016

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

Michael O'Riordan

June 13, 2016

News Daily News

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Michael O'Riordan

June 13, 2016

News Daily News

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Michael O'Riordan

June 13, 2016

Advertisement

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

New A-fib Performance and Quality Measures Emphasize Shared Decision-Making, Inpatient and Outpatient Care

FDA Warns of Class I Recall for HeartWare VAD Batteries

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Black Individuals Have Less A-fib, but When They Do, the Consequences Are More Dire

TAVR 后持续低流量主动脉瓣狭窄与较高的 1 年死亡率相关

Persistent Low-Flow Aortic Stenosis After TAVR Linked With Higher 1-Year Mortality

La Estenosis Aórtica Persistente de Bajo Flujo Post-TAVR se asocia a una Mortalidad Más Alta al cabo de 1 Año

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content